Loading patent…
AssigneesCsir, University of Cape Town, Onderstepoort Biological Products Soc Ltd
InventorsAlbertha René VAN ZYL, Ann Elizabeth MEYERS, Daria Anna RUTKOWSKA, Edward Peter RYBICKI, Hester Catharina STARK, Martha Magaretha O'KENNEDY, Nobalanda Betty MOKOENA
Estimating the term…
This invention relates to a second generation, plant-produced synthetic Orbivirus candidate vaccine. The vaccine comprises a plant produced chimaeric Orbivirus virus like particle (VLP) comprising at least one structural protein from one Orbivirus serotype and at least one structural protein selected from another serotype of the Orbivirus, wherein both structural capsid proteins are from the same Orbivirus species. In particular the invention relates to a vaccine against an Orbivirus, a method of producing chimaeric Orbivirus virus-like particles (VLPs) for use in a method of prevention and/or treatment of an Orbivirus infection, the use of the chimaeric Orbivirus VLPs in the manufacture of a vaccine for an Orbivirus, and a method of preventing and/or treating an Orbivirus infection.
A chimaeric African Horse Sickness Virus (AHSV) virus-like particle (VLP) comprising VP2, VP3, VP5 and VP7 structural proteins, wherein at least one of the VP2, VP3, VP5 and VP7 structural proteins is selected from a first AHSV serotype and at least one of the VP2, VP3, VP5 and VP7 structural proteins is selected from a second AHSV serotype.
-10. (canceled)
12-23. (canceled)
(canceled)
A transformed plant cell comprising at least one expression vector adapted to express a codon optimised nucleotide sequence encoding AHSV VP2, VP3, VP5 and VP7 structural proteins, wherein at least one of the VP2, VP3, VP5 and VP7 structural proteins is selected from a first AHSV serotype and at least one of the VP2, VP3, VP5 and VP7 structural proteins is selected from a second AHSV serotype.
Dependencies are inferred from the claim text.